Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF, Cusi K, Mari A, Foley JE, DeFronzo RA. Balas B, et al. Among authors: foley je. J Clin Endocrinol Metab. 2007 Apr;92(4):1249-55. doi: 10.1210/jc.2006-1882. Epub 2007 Jan 23. J Clin Endocrinol Metab. 2007. PMID: 17244786 Clinical Trial.
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
Azuma K, Rádiková Z, Mancino J, Toledo FG, Thomas E, Kangani C, Dalla Man C, Cobelli C, Holst JJ, Deacon CF, He Y, Ligueros-Saylan M, Serra D, Foley JE, Kelley DE. Azuma K, et al. Among authors: foley je. J Clin Endocrinol Metab. 2008 Feb;93(2):459-64. doi: 10.1210/jc.2007-1369. Epub 2007 Nov 27. J Clin Endocrinol Metab. 2008. PMID: 18042650 Clinical Trial.
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.
El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D, Nauck MA. El-Ouaghlidi A, et al. J Clin Endocrinol Metab. 2007 Nov;92(11):4165-71. doi: 10.1210/jc.2006-1932. Epub 2007 Aug 14. J Clin Endocrinol Metab. 2007. PMID: 17698900 Clinical Trial.
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
Utzschneider KM, Tong J, Montgomery B, Udayasankar J, Gerchman F, Marcovina SM, Watson CE, Ligueros-Saylan MA, Foley JE, Holst JJ, Deacon CF, Kahn SE. Utzschneider KM, et al. Among authors: foley je. Diabetes Care. 2008 Jan;31(1):108-13. doi: 10.2337/dc07-1441. Epub 2007 Oct 1. Diabetes Care. 2008. PMID: 17909087 Clinical Trial.
347 results